Podcast 22 Sep 2023
Beyond Biotech podcast 64 – Precision immuno-oncology therapies
Despite the huge commercial success of PD-1 inhibitors and widespread use of checkpoint inhibitors such as anti-PD-1 or anti-CTLA4, 70 to 80% of patients still experience limited or no response…